Clobazam as a twice-a-day dosage (10 mg-20 mg) regimen and Diazepam in a thrice-a-da y schedule (j mg-5 mg-5 mg) were bot"i effective in controlling moderate to severe anxiety neurosis. 83 pitients were studied in a controlled, randomised, double-blind trial. Patients received active drug for the first sixweeks and placebo for the next two weeks. Weekly evaluation was performed clinically for anxiolytic effect as wel 1 as effect on motor coordination studied on the PursuitRotor.
Newer benzodiazepines are being introduced for the treatment of anxiety neurosis. The effort to establish more than "me too" drugs is always present. In clinical practice an achievement in -less-side effects or better patient compliance would be a significant contribution to therapeutics.
Clobazam is a relatively new benzodiazepine, which is being investigated in India* Previous studies (de Figueiredo et.al, 1981; Doongaji et aL, 1978) have shown the drug has good anxiolytic effect even during withdrawal from treatment. In these studies a dose of 30 mg in equally divided doses per day has been studied. In view of its prolonged efficacy, we were interested to study the anxiolytic efficacy of 30 mg Clobazam as two divided doses of 10 mg and 20 mg per day. It was also important to determine if the administration of 20 mg Clobazam at night, could have any effect on motor coordination.
Clobazam is unique in its structural relationship to the general class of benzodiazepines. It has a nitrogen atom in the "V position, instead of the '4' position, which may contribute to the differential effects on the desired tranquillising, or taming behaviour and the undesired effects on motor coordination.
The trial was specially designed to study the efficacy of the twice-a-day regimen of Clobazam, any effects on motor coordination, and the anxiolytic activity during drug withdrawal.
METHODOLOGY
Eighty-three adult outpatients diagnosed as anxious neurotics entered the study. By random allocation, patients received either Clobazam as 10 mg at morning and 20 mg at night or Diazepam as 5 mg three times a day. To maintain double-blind conditions, the double-dummy technique of drug administration was used. Each patient therefore received numerically two capsules three times a day, corresponding to the respective doses of Clobazam and Diazepam.
Patients with clinical evidence of severe hepatic, renal or cardiovascular pathology, or organic brain damage, were excluded. A history of drug abuse, affective psychosis or benzodiazepine sensitivity also excluded patients from entry. Pregnancy or its possibility did not permit inclusion of such females into study. Patients who were already on anxiolytic therapy underwent a one week wash out on placebo.
For inclusion, a patient had to be diagnosed as an anxious neurotic, with a score of at least 14 on the Hamilton Anxiety Rating Scale (HARS) (Hamilton, 1959) , as well as at least two on the items of anxious mood and general somatic (muscular and sensory). Treatment was administered by randomisation in packets specially packed for each patient for the 7-days of the week. Active drug treatment was for sixweeks followed by two-weeks treatment on placebo.
Efficacy evaluation was done at the end of each week on the HARS, by the Research Worker, as well as on the Clinical Global Impression Scale (CGI) (ECDEU Assessment Manual, 1970) by the principal investigator.
At each evaluation period, motor coot dination was tested on the Koerth's Pursuit Rotor.
Patients underwent each time a familiarisation trial run (30 sees). Subsequently, the mean of 3 trials was considered as an assessment.
RESULTS

Demography
Out of 83 patients who entered the study, 40 received Clobazam, and 43 received Diazepam. Groups were comparable for demographic variables as seen in Table I . Seven patients (5 in Clobazam group and 2 in Diazepam group) had duration of illness less than 1 month while 18 patients (8 in Clobazam group and 10 in Diazepam group) had duration more than 2years. These patients were also included in the analysis. 
Clinical Assessment
Both drugs significantly reduced the basal score of anxiety on the HARS at the end of 6 weeks treatment. The onset of activity was seen for both drugs at the end of 8 days. At the end of 6 weeks of treatment, patients on Clobazam showed 71 per cent improvement and those on Diazepam improved by 67 per cent (Table 2) .
At the end of further 2 weeks during which patients received placebo, the Clobazam treated group continued to improve by 11 per cent. Further improvement in the Diazepam series was 4 per cent.
The HARS was subjected to further analysis on the clusters of psychic and somatic anxiety. By Wilcoxon's Signed RankTest, significant improvement was seen for both groups (starting with week 1 till the end of 6 weeks treatment). To assess continuing drug effect during the 2 week period on placebo, the Sum of Improvement Scores (SIS) was calculated on the principle of Sum of Reduction Scores used by Doongaji et al. (1978) .
Clobazam treated patients had a higher sum of improvement on the total HARS, as well as %n the clusters of psychic and somatic anxiety (Table 4) . During this period, six variables of the HARS-fear, intellect, depressed mood, general somatic (sensory), cardiovascular and respiratory continued to respond to Clobazam. Against this, only two symptoms, gastrointestinal and behaviour at interview (general) showed improvement in patients on Diazepam. In both the treatment groups, continued therapeutic effect was seen for insomnia and general somatic (muscular). On the Clinical Global Improvement (CGI) Scale, more patients showed moderate and marked improvement on Clobazam. On Days 50 and 57, signiiicantly more patients showed modrate and marked improvement after receiving Clobazam (p<0.06) ( Table 5) . The Sum of Improvement Scores of motor performance on the Pursuit Rotor was calculated for both drug treated groups during withdrawal based on average for the populations. The Sum of Improvement Scores in patients on Clobazam was 78 and in the Diazepam treated patients was 33, at the end of the 2 week drug free period (Table 6 ). Thus motor performance continues to improve in both Clobazam and Diazepam groups after stopping the anxiolytic medication, the improvement being relatively more in subjects who were on Clobazam. (Table 7) . Both drugs did not adversely affect any clinical chemistry parameters. :i (7.14%)
DISCUSSION
Data from the study on both the clinical as well as the motor performance testing show Clobazam is an effective agent, with good maintenance of anxiolysis in the twice-a-day dosage regimen.
On the HARS as well as on the two clusters of psychic and somatic anxiety, both drugs show good anxiolytic effect by Day 8. Patients who received Clobazam showed a trend for better maintenance of therapeutic effect till the end of the two-week post-treatment period on placebo.
. Both de Figueiredo et al. (1981) and Doongaji and associates (1978) observed this phenomenon after 4 weeks treatment with Clobazam followed by one week on placebo. Our study demonstrates that the drug has prolonged anxiolytic activity long after treatment is stopped. This action ensures the smooth transition to the non-drug state, when treatment requires to be stopped or as is encountered in common practice when patients forget to take their medication. Clobazam apparently has a strong carry over effect which is observed clinically on the HARS and both clusters of psychic and somatic anxiety.
On motor performance testing, the better trend for improving function is observed during the post treatment period in patients who received Clobazam. This could be attributed to the good anxiolysis with Clobazam affecting especially somatic symptoms like tremor. The corresponding somatic variable, general somatic (muscular) also showed significant improvement after treatment with Clobazam, and continued to improve during withdrawal.
The good carry over effect of Clobazam may be due to its active metabolite. The parent compound itself has a long-life of 18 hours. Pharma cological studies have shown the metabolite N-desmethyl Clobazam is active in animal experimentation (Fielding and Hoffman, 1979) and has receptor binding potency similar to the parent compound (Hunt, 1979) .
From pharmacokinetic studies, the half-life of the metabolite is 36-36 hours, and it accumulates to a steadystate level about 8 times higher than the parent compound (Rupp et al., 1979) . This data explains good maintenance anxiolytic effect of Clobazam and also the improvement which was seen during the withdrawal stage.
Throughout evaluation,higher trends have been observed on anxiolytic effect, motor coordination and maintenance of therapeutic response after treatment was stopped in patients who have received Clobazam. The results are clinically significant, especially in the light of comparisons made between two active drugs than between active drug and placebo.
Drowsiness occurred with equal frequencey in both the treatment groups. It seemed worthwhile to study the reasons for drop-outs where available to ascertain any cause-effect relation to the drugs under study. Out of the 8 drop-outs who received Clobazam, only one complained of severe drowsiness. 5 patients out of 15 on Diazepam dropped out due to drowsiness.
This trial suggests a dose of Clobazam as 10 mg at morning and 20 mg at night does not produce any detrimental effect on motor coordination with respect of Diazepam (15 mg) in 3 equally divided doses. The effect of Globazam is well maintained after treatment is discontinued, so that there is no risk of a worsening of anxiety, in the event of a patient forgetting to take medication. The twice-a-day schedule is a forward step in improving patient compliance.
Perhaps Clobazam can be called a "better" anxiolytic, since it meets the conditions for "better" as defined by Vinar (1973) . "It affects some symptoms in a more intensive way, its therapeutic effects endure longer, it has fewer side-effects, and is simpler to administer."
